For ITP management, the American Society of Hematology (ASH) clinical practice guidelines recommend initial pharmacological treatment with corticosteroids with or without intravenous immunoglobulin (IVIG) followed by second-line therapies, including thrombopoietin receptor agonists (TPO-RAs), rituximab, or splenectomy for non-responders or those dependent on corticosteroids with platelet counts < 30 × 109/L (5). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.